Market Cap 3.40B P/E - EPS this Y 66.70% Ern Qtrly Grth -
Income -8.71M Forward P/E -99.84 EPS next Y -962.50% 50D Avg Chg -9.00%
Sales - PEG -13.24 EPS past 5Y 58.11% 200D Avg Chg 47.00%
Dividend N/A Price/Book 12.07 EPS next 5Y 83.80% 52W High Chg -42.00%
Recommedations 2.00 Quick Ratio 106.97 Shares Outstanding 40.01M 52W Low Chg 2,953.00%
Insider Own 6.49% ROA -3.63% Shares Float 37.43M Beta 1.14
Inst Own 27.74% ROE -5.69% Shares Shorted/Prior 4.42M/3.76M Price 84.86
Gross Margin - Profit Margin - Avg. Volume 3,497,982 Target Price 116.20
Oper. Margin - Earnings Date Aug 10 Volume 10,269,124 Change 6.10%
Cassava Sciences, Inc. News
07:03 PM SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
01:38 PM Is Cassava Sciences Stock a Buy Right Now? This Is What You Need to Know
10:42 AM Why Former NYSE Trader David Green Bought NVIDIA, Tesla, and Cassava Sciences On Tuesday
07:30 AM Cassava Sciences Reports Second Quarter 2021 Financial Results
05:06 AM 5 Ultra-Popular Stocks to Avoid Like the Plague in August
08/02/21 Cassava Sciences Announces Conference Call for Second Quarter Financial Results
08/02/21 15 Most Volatile Stocks To Buy Now
07/31/21 S&P Rises More Than 2% in July
07/29/21 Top Small-Cap Stocks for August 2021
07/29/21 Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
07/29/21 Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease
07/29/21 Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease
07/29/21 Cassava Sciences Is Overbought But Still Points Higher
07/28/21 11 Best Pharma and Biotech Stocks to Buy According to Jim Simons’ Euclidean Capital
07/27/21 Cassava Looks to Extend Breakneck Rally on Alzheimer’s Data
07/27/21 Cassava: Alzheimer’s Diagnostic Test Could Add Another Feather to the Cap
07/26/21 Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam
07/23/21 Cassava Sciences Stock Could Be Worth $900 After Its Upcoming Alzheimer’s Results
07/23/21 Why Annovis Stock Is Bucking The Trend In Alzheimer's — And Two Others To Watch

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.

SAVA Chatroom

User Image ChartMill Posted - 18 minutes ago

$SAVA has an average volume of 4309740. This is a good sign as it is always nice to have a liquid stock.

User Image betachaser Posted - 46 minutes ago

$SAVA 40 million shares, 3.4 billion market cap for a drug that would bring in 40-50 billion in revenue per year. Even with only 50 people in the trial, getting better after 9 months is nothing short of a miracle. Alzheimer patients simply do not get better at 9 months. Looked at other recent attempts that failed (Lundbeck, failed in Phase 3), but none came close to these kind of results, and had this kind of safety profile. Big boom coming. 12 month data due in Sept?

User Image BetterInvestor Posted - 53 minutes ago

$SAVA BOOM! $900!!!!

User Image KMAPK Posted - 1 hour ago


User Image KMAPK Posted - 1 hour ago


User Image KMAPK Posted - 1 hour ago


User Image KMAPK Posted - 1 hour ago

$SAVA some DD for the group as a reminder of how great this opportunity is for you and people struggling with AZ

User Image KMAPK Posted - 1 hour ago


User Image Millionaireadonis Posted - 1 hour ago


User Image WallStreetOdds_ Posted - 1 hour ago

$SAVA Out of the 171 other times SAVA was up 7.1% during a trading day, 58% of the time it traded lower by the next day's market close.

User Image AboveTheHorizon Posted - 1 hour ago

$SAVA closed well. Back to 3 weeks ago. Seems about right. Staying long since $10. Grabbed some $100 and $145 august calls today to boot. Like my chances.

User Image KMAPK Posted - 2 hours ago

$SAVA the buyout of this company would have to be in the 20 billion mark at this stage with their results and potential. Next year 60 billion with FDA approval and revenues. 100 billion in 2023 IMO of course. 20 billion / 40 million shares = 500 PPS 60 billion / 40 million shares = 1500 PPS 100 billion / 40 million shares = 2500 PPS Currently 3.4 billion - PPS $85 This company is dirt cheap and oversold with great news coming. Patience will pay off here. Don’t fall for the short term games played. Set a sell order for 500 per share and leave it.

User Image HitAHomerun Posted - 2 hours ago

$SAVA still not convinced…..neutral….

User Image Huskymum Posted - 2 hours ago

$SAVA Clearly remember a folk who posted here yesterday: you can short a stock why not? so what? but plz be a decent man! short a kind of medication which 50000000 patiants and their beloved family are wating for over the world? not cool! thing goes around comes around, remember that.

User Image allcharts Posted - 2 hours ago

$SAVA SAVA 2021-08-03 Options Analysis Video:

User Image savvvaayyvvvay Posted - 2 hours ago


User Image ChartMill Posted - 2 hours ago

An Altman-Z score of 670.82 indicates that $SAVA is not in any danger for bankruptcy at the moment.

User Image 100fold Posted - 2 hours ago

$AVXL I hear a lot of people disgruntled with CM and his cautious approach, but wow! This last week shows us his wisdom. I didn’t realize how treacherous the biotech swamp was until $ANVS and $SAVA blew up with the subsequent shareholder lawsuits and unknown fallout still to come. The recklessness of $SAVA and $ANVS CEO’s should be a warning to long term investors in $AVXL. The silver lining for $AVXL is that we may have bought ourselves more time to accumulate shares on the cheap.

User Image SladeMcGherkinnn Posted - 2 hours ago

$SAVA found fraudsteins stocktwits account

User Image hankscorpio81 Posted - 2 hours ago

$SAVA Breaking news: High-tier law firm starts investigation into the data fudging of medical trials belonging to Cassava Sciences. "We will seek to recoup the capital of investors who placed trust in the muddy data Cassava Sciences has presented over the last 6 months," a lead lawyer connected to the case was quoted as saying.

User Image SladeMcGherkinnn Posted - 3 hours ago

$SAVA “is Remi driving a train up your suddenly newly widened short selling asshole? Call 1-800-MORON to speak with the pomerantz law firm RIGHT NOW!!!”

User Image DeeAnthony805 Posted - 3 hours ago


User Image Huskymum Posted - 3 hours ago

$SAVA Only copycat or 5yr old kid would’ve done things like that lol, shorts are pathetic!

User Image betachaser Posted - 3 hours ago

$SAVA lol at idiots reposting Pomerantz…. You have to be a clueless turd, they are like bots that spam any stock that has had a price crash. Literally no company they haven’t ‘investigated’

User Image SladeMcGherkinnn Posted - 3 hours ago

$SAVA can someone kindly pull the wool off of @safado s eyes? He’s drooling in his oatmeal again 🤡

User Image SladeMcGherkinnn Posted - 3 hours ago

$SAVA shorts losing their ass are desperate enough to cling to obvious spam 🤡

User Image LiesallLies007 Posted - 3 hours ago

$SAVA yeah Pomerantz is here...

User Image arisegern Posted - 3 hours ago

$SAVA almost bought a put at 140 I need more balls seriously though

User Image safado Posted - 3 hours ago

$SAVA WOOT! There it is. A day too late. Expect more of these.

User Image SladeMcGherkinnn Posted - 3 hours ago

$SAVA same thing happening to ANVS….it’s spam

Analyst Ratings
HC Wainwright & Co. Buy Jul 20, 21
B. Riley Securities Buy Jun 23, 21
B. Riley FBR Buy Apr 27, 21
JonesTrading Buy Mar 17, 21
HC Wainwright & Co. Buy Feb 23, 21
Maxim Group Buy Feb 16, 21
HC Wainwright & Co. Buy Feb 16, 21
Cantor Fitzgerald Overweight Oct 23, 20
HC Wainwright & Co. Buy Sep 23, 20